Search

for
Search:

Glossary S100A3

protein in hair cuticles involved in growth and structure

S100A3 is a protein that belongs to the S100 family, which is known for its role in calcium-binding. This particular protein is highly expressed in human hair cuticles and is thought to be involved in hair growth and structure. It can bind to both calcium and zinc, which may influence hair's physical properties and resilience.

Related Terms

Sort by

Community Join

30 / 1000+ results

community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga

in Technology 9 upvotes 7 months ago

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

community SUBE3 for sale in the gray market?

5 upvotes 1 year ago

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

community Best available SARD right now?

in Treatment 3 upvotes 4 months ago

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

community PP405 (Everychem 3HP) Anecdotes - Please assemble and share your story

in Chat 107 upvotes 5 months ago

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

community A warning to anyone considering 3rd party sourcing PP405 or its analogs

30 upvotes 5 months ago

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

community SCUBE 3 (the last hair bender)

2 upvotes 1 year ago

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

community Where are we with GT20029 ? Realistic Timeline ?

9 upvotes 11 months ago

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

community AH-001 another topical AR degrader beside GT20029, completed Phase I

8 upvotes 10 months ago

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

community Pp405 trials question - 2a/2b,

6 upvotes 10 months ago

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

community Why there are no updates from Amplifica about SCUBE3 & AMP-303?

5 upvotes 11 months ago

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

community Amplifica and AMP-303 clinical phase 1

9 upvotes 2 years ago

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

community RU-58441 Janoshik test result of Made-In-China Supplier

29 upvotes 9 months ago

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

community PP405 (Everychem 3HP) Users - Assemble and share your story!

in Chat 19 upvotes 4 months ago

Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.

community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news

13 upvotes 9 months ago

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

community Trial for TDM-105795 update from research office

16 upvotes 2 years ago

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

133 upvotes 2 years ago

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

community Any updates or news on Gt20029?

6 upvotes 1 year ago

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

community PP405 (Everychem 3HP) users - assemble and share your updates!!

in Chat 44 upvotes 4 months ago

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

community Hope Medicine's HMI-115 could be out in 2027 per Company Founder

34 upvotes 1 year ago

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

community Wrap it up everyone. CB-03-01 is another failed treatment

79 upvotes 1 year ago

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

community Why doesn't phase 3 of PP405 start straight away?

in Chat 14 upvotes 8 months ago

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

community Pp405 any site for buying in Europe

4 months ago

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

community where/how to buy Cb-03-01 for "research purposes"?

8 months ago

The conversation is about purchasing Cb-03-01 for research purposes. The user seeks advice on where and how to buy it outside the U.S.

community How many years can we expect PP405 to be on the market

11 upvotes 1 year ago

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

community Black market pp405? Title title

in Treatment 8 upvotes 8 months ago

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

community PP405 gets its generic name - Suvomipic

287 upvotes 1 month ago

Suvomipic, previously known as PP405, is progressing to Phase 3 trials for hair loss treatment. Its effectiveness compared to existing treatments like Minoxidil and Finasteride is still uncertain.

community PP405 (Non) Update - Feb 2025

36 upvotes 1 year ago

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

community HopeMed (Hmi115) is pissed at Absci (Abs-201)

4 upvotes 2 weeks ago

HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.

community Ru vendor? Looking for a cheaper source

in Product 3 upvotes 1 year ago

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

community CB-03-01 / Breezula Personal Results

17 upvotes 7 months ago

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.